W 7 (W7)

01/01/1986 - "TPA-induced skin tumor promotion was also suppressed by W-7. "
01/01/2001 - "ER variants of the 21PT type were detected among breast cancer biopsy specimens, emphasizing the significance of an alternative therapeutic target for TAM-resistant ER (+) human breast cancers with compounds such as W7."
01/01/1991 - "These findings raise the possibility that W-7 may have clinical value in the prevention of cancer metastasis."
01/01/1991 - "Injection of W-7 i.v. after removal of the implanted primary tumor caused the greatest inhibition of development of lung metastases. "
01/01/1988 - "Although treatment with cisplatin alone markedly inhibited lytic activity of the spleen cells in tumor-bearing nude mice against the tumor cells, the inhibitory effect was eliminated by subsequent treatment with W-7. "

10/01/1994 - "The effect of 50 microM W-7 was additive to that of a submaximal (20 min) hypoxia stimulus, indicating that W-7 does not interfere with the stimulation of glucose transport by hypoxia. "
07/01/1986 - "Addition of trifluoperazine (5 X 10(-7) M) and W7 (5 X 10(-7) M to both PST and CCT cells during the 2-hr reflow period after 45 min of anoxia increased viability by 58 +/- 3 and 62 +/- 3%, respectively (P less than .05) at 5 hr postanoxia.(ABSTRACT TRUNCATED AT 250 WORDS)"
05/01/1986 - "W-7 (5 X 10(-6) M) and chlorpromazine (10(-6) M) did not affect the AH intervals before hypoxia. "
05/01/1986 - "W-5, a chlorine-deficient derivative of W-7, showed no protection against hypoxia-induced AV nodal conduction disturbances. "
10/01/1994 - "This study was performed to describe the interactions between the effects of W-7 and those of hypoxia and of insulin on glucose transport. "

07/01/2007 - "In adrenalectomized rats, W-7 was also effective in reduction of paw edema (52%). "
12/01/1994 - "When applied before irradiation, W7 and TFP prevented edema in Skh-1 mice and W7 prevented UV-induced edema in NSA mice in a dose-dependent manner. "
07/01/2007 - "Treatment of animals with W-7 reduced carrageenan-induced paw edema by 50%. "
07/01/2007 - "The aim of present study was to investigate the effect of W-7, a calmodulin antagonist, on carrageenan-induced rat's paw edema. "
07/01/2007 - "Our findings suggest that W-7 as a calmodulin inhibitor reduce carrageenan-induced paw edema and the inhibitory effect of W-7 on edema formation appears not to be dependent on adrenal function."

12/01/1991 - "The comparable IC50 of W-7 to inhibit cell growth of vascular smooth muscle cells of both origins indicates that the defect may not be due only to calmodulin, and furthermore suggests the involvement of a previously-reported calmodulin activator in hypertension."
02/01/1989 - "The suppressive magnitudes in these responses by W-7 were significantly greater in the mesenteric vasculatures of the DOCA-salt hypertension than in those of the control rats. "
01/01/2021 - "While there was no change in mean HbA1c or prevalence of diagnosed hypertension (type 1 diabetes: W1, 22.7%; W7, 19.9%; type 2 diabetes: W1, 60.9%; W7, 66.2%), the use of statins had increased among patients diagnosed with dyslipidaemia (type 1 diabetes: W1, 77.7%; W7, 90.7%; type 2 diabetes: W1, 78.6%; W7, 94.7%). "
08/01/1990 - "Although i.v. injection of the drugs did not produce any effect, infusion of W-7 or KN-62 into the 4th ventricle produce any effect, infusion of W-7 or KN-62 into the 4th ventricle of the rat caused hypertension and tachycardia, associated with the diminished rate of GABA release in cerebrospinal fluid. "
01/01/1988 - "The marked reduction in norepinephrine overflow and pressor responses by W-7 might suggest the greater calmodulin-dependent adrenergic transmission in this model of hypertension."

06/01/1990 - "Despite the fact that training time and volume were equal, the training group showed a significantly greater improvement in force (from 91 to 94 N, 3.3%), velocity (from 1.75 to 1.81 m.s-1, 3.4%) and power (from 160 to 172 W, 7%) as measured on the MAD-system, and an increase in distance per stroke in free swimming. "